Jul 18,2023

Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment through AI and Clinical Trial Accessibility

Massive Bio and CureMatch, a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, have joined forces in a transformative partnership aimed at revolutionizing cancer treatment. In this game-changing alliance, CureMatch will harness its distinctive platform to identify patients who stand to benefit most from groundbreaking clinical trials, thereby magnifying the reach and impact of Massive Bio's trials. Simultaneously, Massive Bio will employ its cutting-edge AI capabilities to process a wealth of patient clinical health data, including variables such as cancer type, demographics, geographic location, and historical data.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 27,2023

Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care and Clinical Research

Massive Bio and Datavant, the leader in helping organizations securely connect data, are thrilled to announce an expanded partnership that leverages Datavant’s national scale in medical record retrieval and Massive Bio’s expertise in AI-driven clinical trial matching to accelerate clinical research and improve patient care in cancer. This expanded partnership builds upon an earlier pilot that enabled Massive Bio to request, retrieve, and digitally deliver clinical data with higher reliability, faster speed and greater coverage across sites of care, thus significantly improving patient outcomes while ensuring compliance and data privacy. With this expanded partnership, Massive Bio will integrate Datavant’s medical record retrieval capabilities into Massive Bio’s operations in order to expedite the identification of potential clinical trial participants and speed up time to insight in clinical research.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 05,2023

Flatiron welds deal with Lifebit to leverage AI in tracking cancer data

Flatiron Health has inked a multiyear deal with Lifebit, which uses AI to collect biomedical data to advance research and development of treatments targeting cancer. The collaboration will use Lifebit’s technology platform to collect data from hospitals, healthcare providers, research organizations and clinical trials that can then be used in drug development and improved patient care, the companies said in a May 31 press release. Lifebit’s platform is currently being used to support research initiatives by Genomics England, the Danish National Genome Center and NIHR Cambridge Biomedical Research Center. It allows researchers and clinicians to securely analyze data at its point of origin while connecting other data sets without the data being moved or copied.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023 TOP STORY

Flatiron expands oncology work to UK with collaboration deal

Health technology company Flatiron has expanded its global footprint as part of a collaboration deal with Leeds Teaching Hospitals NHS Trust, one of the largest acute hospital trusts in Europe. The goal of the partnership is to produce high-quality oncology data sets that can be used in research collaborations and under license with biopharma companies in order to speed cancer research. Flatiron currently has operations in Japan, Germany and the U.K. that partner with hospitals and health networks in RWD collaborations. In May, Flatiron signed a deal with Sanofi to redesign oncology trials, and in early June the company partnered with AI-focused Lifebit to advance research and development of treatments targeting cancer.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Belong Announces Two Studies Based on RWD at ASCO 2023

Belong.Life has announced that the American Society of Clinical Oncology (ASCO) has published two abstracts in its 2023 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app. The first study (abstract 6592) examined the prevalence of restrictive behavioral practices among cancer patients, analyzing restrictions related to interactions with others, visiting public places and more. The second study (abstract e18774) explored patients’ awareness of the heightened risk of developing a cancer associated thrombosis (CAT) event, a potentially fatal complication in which the pro-coagulation properties in cancer cells along with anti-cancer treatments contribute to the development of blood clots. “Most quality-of-life assessments used today do not measure patients’ ability to maintain normal daily activities during treatment, rather they focus on rigid health-related criteria,” explained Belong.Life Medical Director and Co-author of the study, Dr. Daniel Vorobiof, "This study highlights for pharmaceutical companies, medical researchers and clinical investigators the importance of including real-life quality of life assessments as additional endpoints in clinical trials.”

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023

COTA-Powered Research will be Presented at the Annual Congress of the European Hematology Association

The fruits of COTA’s expanded research and consulting services — Real-World Insights and Real-World Support — will be on display at the annual Congress of the European Hematology Association (EHA) being held in Frankfurt and online June 8-11. DLBCL is the most common subtype of non-Hodgkin lymphoma. Standard of care for frontline therapy remains chemoimmunotherapy; however, nearly half of the patients will experience relapse or refractory (R/R) disease. A research team from COTA and Merck Sharp & Dohme, a subsidiary of Merck & Co., analyzed RWD from 1347 eligible patients, the majority of whom (81.3%) received treatment in the community practice setting. The study concludes that there is a significant need for improved therapy options for patients who do not respond to the current initial standard of care.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Research featuring Elekta’s Kaiku Health platform to be presented at ASCO 2023

Personalized digital patient monitoring and support has become an important part of clinical research and routine care for growing number of patients globally. That’s why Kaiku Health are excited to be a part of clinical research published at ASCO 2023 in the two following sessions: Use and value of self-management recommendations in a real-world evidence study evaluating digital patient monitoring of patients receiving cancer care, and An interventional study of digital patient monitoring impact on health outcomes and healthcare resource utilization, and feasibility of combination with at-home treatment, in patients receiving systemic anticancer treatment in clinical practice.

CONFERENCES

#rwd

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Caris Life Sciences and ConcertAI Expand Partnership to Create First-in-Class, Prospectively Matched Clinico-Genomic Research Platform

Caris Life Sciences, the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, today announced an expanded translational sciences and clinical development solutions partnership. In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools. PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson/Janssen, Novartis, and Roche. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

New Data from Immunotherapy Quality of Life Study Accepted for Two Abstracts at 2023 ASCO

The Wave Health digital health platform, used to collect patient symptom and quality of life information in an innovative research study, comprises two abstracts accepted to the 2023 ASCO Annual Meeting. The study used TTI’s electronic patient reported outcomes (ePRO) platform to measure a variety of symptoms and aspects of health-related quality of life (HRQoL) in the “ImmunoWave” study, conducted at Fred Hutchinson Cancer Center. The study assessed for the presence of eleven symptoms and overall quality of life in a group of participants with prior exposure to ICI therapy or ongoing long-term ICI treatment. Participants in the study completed weekly symptom and HRQoL assessments using Wave Health. Participants reported frequent, persistent, and often severe symptoms, most notably fatigue, mental health symptoms and musculoskeletal symptoms. The study also identified which symptoms appeared to correlate most with diminished quality of life.

CLINICAL STUDY

#rwd

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD